Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

Investor Relations


$15.75 - 0.15
Volume: 98,700
Mar 6, 2015 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics targeting both cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinical stage product candidates, SL-401 and SL-701, and a pipeline of preclinical candidates including SL-801 and SL-501.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of a wide range of hematologic cancers. Three multicenter clinical trials with SL-401 are currently open in the following indications: 1) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory acute myeloid leukemia (AML), the expansion stage of which may serve as a registration trial for BPDCN; 2) AML patients in first complete remission (CR) with minimal residual disease (MRD); and 3) four types of advanced high-risk myeloproliferative neoplasms (MPN), including systemic mastocytosis, advanced symptomatic hypereosinophilic disorder, myelofibrosis, and chronic myelomonocytic leukemia. Additional SL-401 studies are currently planned in myeloma and certain other lymphomas and leukemias. Previously, SL-401 demonstrated single-agent activity, including multiple durable complete responses (CRs), in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML.

SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open and accruing adult patients with glioblastoma multiforme (GBM) in first recurrence. Additional SL-701 studies are currently planned in pediatric high-grade glioma. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers.

Preclinical candidates being advanced toward investigational new drug (IND) filings include SL-801 , a novel, oral small molecule reversible inhibitor of XPO1, being developed for solid and hematologic cancers, and SL-501, a next generation IL-3R targeted therapy, being developed for oncologic and certain autoimmune indications.

Corporate Snapshot

PDF Corporate Snapshot

Corporate Presentation

PDF Corporate Presentation – March 2015

View all »   RSSRecent Releases

Mar 6, 2015
Stemline Therapeutics to Present at the 27th Annual ROTH Conference

Feb 26, 2015
Stemline Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

View all »Events & Presentations

Mar 9, 2015 at 4:30 PM ET
27th Annual ROTH Conference

Mar 10, 2015
Corporate Presentation – March 2015

Copyright 2015 - Stemline Therapeutics, Inc. All rights reserved